Imaging Services for Checkpoint Molecules in TME
Targeting the checkpoint molecules with immune checkpoint inhibitors has emerged as a promising strategy for cancer immunotherapy. At Alfa Cytology, we assess the expression and distribution of these molecules, providing valuable insights into the tumor-immune interactions and aiding in the development of personalized treatment strategies.
Introduction to Checkpoint Molecules
Checkpoint molecules and their corresponding ligands play a critical role in regulating immune responses within the tumor microenvironment (TME).
Targeting PD-1 and CTLA-4 for Enhanced Tumor
Immunity
Well-known checkpoint molecules include programmed death-1 (PD-1) PD-1, which suppresses T cell activation, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which inhibits T cell activation. These molecules regulate immune responses and can be targeted to enhance anti-tumor immunity.
Exploiting LAG-3, TIM-3, TIGIT for Cancer
Immunotherapy
Other molecules like Lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), and T cell immunoreceptor with Ig and ITIM domains (TIGIT) can also be targeted to improve immune responses against tumors.
Fig.1 Important inhibitory immunoreceptors (immune checkpoints), their ligands and known signaling mechanisms. (Köhler N, et al., 2021)
Additionally, the expression of checkpoint molecules in the TME can be used as a biomarker to predict patient response to immunotherapy. For instance, it has been observed that high PD-L1 expression within the TME is associated with a more effective response to PD-1/PD-L1 blockade therapy.
Our Services
Alfa Cytology has the ability to visualize and characterize checkpoint molecule expression patterns within the TME and to support researchers in developing treatment strategies. We employ multimodal imaging approaches that combine different imaging modalities. Our imaging services not only provide visualization of checkpoint molecules but also offer comprehensive molecular profiling.
| Service Options |
Description |
| Targeted Radiotracers for Comprehensive TME Assessment |
Our expertise allows us to develop radiotracers that are specifically designed to target checkpoint molecules such as PD-1 and CTLA-4. These radiotracers selectively accumulate within tumor tissues, allowing for a thorough assessment of the TME. |
| Mapping Checkpoint Molecules in TME |
We employ magnetic resonance imaging (MRI) to assess the distribution and expression of checkpoint molecules in preclinical cancer models. By combining molecular imaging probes with MRI, we support researchers in visualizing the spatial distribution of checkpoint molecules within the TME. |
| Exploring Checkpoint Molecules in Cancer Models for Therapy Efficacy |
We utilize fluorescence imaging to visualize the expression of checkpoint molecules in different mouse cancer models. By labeling checkpoint molecules with fluorescent probes, we can visualize their localization and distribution within the tumor and surrounding tissues. |
Our Advantages
Largest Toolbox
Strong Expertise
One-stop Solution
Short Turnaround
At Alfa Cytology, we apply these imaging technologies to offer customized imaging services for checkpoint molecules in the TME. By doing so, we can assist researchers in acquiring crucial data regarding the expression patterns of checkpoint molecules and their impact on tumor-immune interactions. If you are interested in our service, please contact us for more details.
Reference
- Köhler, N., et al.; (2021). The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation. Frontiers in Immunology, 12, 634435.
For research use only.
Related Services
